Long term efficacy of cornea collagen cross-linking (CXL) in Pellucid Marginal Degeneration (PMD)

Long term efficacy of cornea collagen cross-linking (CXL) in Pellucid Marginal Degeneration (PMD) in improving Topographic findings, Visual Acuity (VA) and Refraction

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT20130306012724N4

Enrollment

Registered

2020-06-04

Start date

2020-06-21

Completion date

Unknown

Last updated

2020-06-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

PMD, Pellucid Marginal Degeneration. Pellucid Marginal Degeneration

Interventions

Intervention group: Patients that underwent CXL. After total manual debridement of the cornea epithelium, the cornea impregnated with riboflavin using the riboflavin 0.1% + Dextran 20% drops instilled

the yellowish glare on slit lamp examination in anterior chamber was utilized to confirm adequate riboflavin penetration to the tissue. The cornea irradiated with ultraviolet A light at 3mW/cm2 and 5.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients that underwent CXL due to mild to moderate PMD before 2015 in Feyz hospital located in Isfahan

Exclusion criteria

Exclusion criteria: History of herpetic keratitis Prior use of hard contact lens History of other ophthalmologic surgeries Inaccessible patient

Design outcomes

Primary

Measure	Time frame
Uncorrected Visual Acuity (UCVA). Timepoint: Before intervention, Present time (after at least 5 years from the intervention). Method of measurement: Snellen chart.;Best Corrected Visual Acuity (BCVA). Timepoint: Before intervention, Present time (after at least 5 years from the intervention). Method of measurement: Snellen chart.;K1. Timepoint: Before intervention, Present time (after at least 5 years from the intervention). Method of measurement: Pentacam topography.;K2. Timepoint: Before intervention, Present time (after at least 5 years from the intervention). Method of measurement: Pentacam topography.;K max. Timepoint: Before intervention, Present time (after at least 5 years from the intervention). Method of measurement: Pentacam topography.;Thinnest. Timepoint: Before intervention, Present time (after at least 5 years from the intervention). Method of measurement: Pentacam topography.;Q value. Timepoint: Before intervention, Present time (after at least 5 years from the intervention). Method of measurement: Pentacam topography.;Sphere. Timepoint: Before intervention, Present time (after at least 5 years from the intervention). Method of measurement: autorefractometry.;Cylinder. Timepoint: Before intervention, Present time (after at least 5 years from the intervention). Method of measurement: autorefractometry.;ISV. Timepoint: Before intervention, Present time (after at least 5 years from the intervention). Method of measurement: Pentacam topography.;IVA. Timepoint: Before intervention, Present time (after at least 5 years from the intervention). Method of measurement: Pentacam topography.;IHA. Timepoint: Before intervention, Present time (after at least 5 years from the intervention). Method of measurement: Pentacam topography.;D. Timepoint: Before intervention, Present time (after at least 5 years from the intervention). Method of measurement: autorefractometry.	—

Measure

Time frame

Uncorrected Visual Acuity (UCVA). Timepoint: Before intervention, Present time (after at least 5 years from the intervention). Method of measurement: Snellen chart.;Best Corrected Visual Acuity (BCVA). Timepoint: Before intervention, Present time (after at least 5 years from the intervention). Method of measurement: Snellen chart.;K1. Timepoint: Before intervention, Present time (after at least 5 years from the intervention). Method of measurement: Pentacam topography.;K2. Timepoint: Before intervention, Present time (after at least 5 years from the intervention). Method of measurement: Pentacam topography.;K max. Timepoint: Before intervention, Present time (after at least 5 years from the intervention). Method of measurement: Pentacam topography.;Thinnest. Timepoint: Before intervention, Present time (after at least 5 years from the intervention). Method of measurement: Pentacam topography.;Q value. Timepoint: Before intervention, Present time (after at least 5 years from the intervention). Method of measurement: Pentacam topography.;Sphere. Timepoint: Before intervention, Present time (after at least 5 years from the intervention). Method of measurement: autorefractometry.;Cylinder. Timepoint: Before intervention, Present time (after at least 5 years from the intervention). Method of measurement: autorefractometry.;ISV. Timepoint: Before intervention, Present time (after at least 5 years from the intervention). Method of measurement: Pentacam topography.;IVA. Timepoint: Before intervention, Present time (after at least 5 years from the intervention). Method of measurement: Pentacam topography.;IHA. Timepoint: Before intervention, Present time (after at least 5 years from the intervention). Method of measurement: Pentacam topography.;D. Timepoint: Before intervention, Present time (after at least 5 years from the intervention). Method of measurement: autorefractometry.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Alireza Peyman

Esfahan University of Medical Sciences

peyman@med.mui.ac.ir+98 31 3445 2031

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026